Can a common parasite drug tackle a stubborn skin disease?
NCT ID NCT06251739
First seen Sep 30, 2025 · Last updated May 25, 2026 · Updated 36 times
Summary
This early-stage trial tested whether ivermectin, a well-known anti-parasitic drug, could safely treat post-kala-azar dermal leishmaniasis (PKDL), a skin condition that can spread the parasite causing kala-azar. Thirty adults in Bangladesh received either ivermectin or the standard drug miltefosine. The goal was to see if ivermectin could clear skin lesions and parasites with fewer side effects and a shorter treatment time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST-KALA-AZAR DERMAL LEISHMANIASIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
International Centre for Diarrhoeal Disease Research, Bangladesh
Dhaka, Dhaka Division, 1212, Bangladesh
Conditions
Explore the condition pages connected to this study.